The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
With all this data available, it seems that Conifer aren’t taking anymore stock. They’ve reduced their position and have not increased during the last placing.
Even more concerning is the European Healthcare fund not triggering a TR1. Clearly they want to be able to sell stock without notifying PIs.
Current significant shareholders are as follows:
Lombard Odier Investment Managers 3.3%
As at 30th April 2024 the company has 360,042,104 ordinary shares of 10p each in issue.
1.3% of the ordinary shares of the Company are not held in public hands.
Avacta Group has not applied or agreed to have any of its securities (including its AIM securities) admitted or traded on any other exchanges or trading platforms.
There are no restrictions on the transfer of Avacta Group plc’s AIM securities.
Avacta Group plc is subject to the UK City Code on Takeovers and Mergers.
Avacta Group plc is incorporated in the United Kingdom and its principal place of operation is the United Kingdom.
This information was last updated on 30th April 2024.
Maybe we can get back to 60p plus
That’s a defeatist mentality, desperately hoping it will go back to 60p. For a stock that previously traded above 100p and was touted to be a paradigm shift. Just wow.
This is a company that should be trading below 20p. Even the bulls don’t believe it’ll get back to 60p.
The CEO carefully crafted his words. What has actually happened, is the company has actively tried to do some deals. Unfortunately nobody was interested and the deals that they were able to do were offered at such a low price it wouldn’t have been worthwhile.
The death spiral overhang and difficulties raising capital is like a dark cloud over this company.
So Alastair if you really have sufficient data to partner the precision platform, why can’t you sign a big deal now?
Don’t have enough data? Or is the data that you have just not good enough? Something just doesn’t add up. Cue LFT.
Been there done that. Smiffy told everyone LFTs demand was going to outweigh supply for the foreseeable future. It turned out that there was no demand because the LFT didn’t work. He didn’t sell any and bring enough cash in.
How can we be sure AVA6000 will work? Why did Neil Bell leave so soon when he had experience of commercialisation?
Smiffy won't be hanging around much longer. He'll be selling shares so he can buy his new house, no doubt. His salary bump last year was to make his mortgage more affordable now there's high interest rates. Just a shame the company he runs is now more affordable.
If the CEO claims that it works unequivocally, then why can’t he get a license deal? He has always said his term sheets would be ready for a licence deal once he started to see that phase 1 data. So can’t he find anyone who’s interested? Or does it not work unequivocally?
As I’ve said before, the so called specialist healthcare fund is probably Ophidian’s SIPP. Nothing to boast about really for someone who equates Avacta to the scandalous British Biotech.
The real kicker is when the city boy said he focuses on whether the company meets its timelines. So now we know the high quality institutions will be majors sellers at any sign of lapse in timeline by the company.
We know the institutions get better visibility of this, so expect major sell offs when these institutions start selling. This is going to drop like a bomb once the market makers figure out what’s going on.